Rattlesnake

pexels.com

How Rattlesnakes Survive Their Own Venom, and Why It Could Save Human Lives

In A Nutshell

  • Rattlesnake blood contains proteins called FETUA that can completely block the lethal effects of rattlesnake venom in mice when combined in the right pairs or trios.
  • No single protein worked alone, but combinations succeeded where individual proteins failed, fully protecting mice from otherwise fatal doses.
  • The proteins also worked against venoms from snakes separated from rattlesnakes by up to 50 million years of evolution, though protection varied by species and failed entirely against one, the African puff adder.
  • In lab tests, the protein combination neutralized venom using about one-tenth the weight of the leading commercial antivenom, though it has not been tested as a treatment after a bite has already occurred.

Rattlesnakes carry a strange kind of insurance policy. Their blood can shrug off their own venom. Scientists have known that for decades but never figured out how to bottle the trick for people. A new study gets closer than anyone has before, pointing to a promising new direction for one of the world’s most neglected health crises, though a usable treatment is still years away.

Snakebite kills roughly 100,000 people every year and permanently disables about 400,000 more. And the standard fix hasn’t changed much since the late 1800s: inject venom into a large animal, collect the immune response it produces, then purify that into antivenom. It works, but it’s expensive, often scarce, and can trigger serious immune reactions of its own. A new study published in the Proceedings of the National Academy of Sciences suggests something hiding in rattlesnake blood might do the job better.

Researchers zeroed in on a group of proteins in Western Diamondback rattlesnake blood called FETUA proteins, descendants of an ancient protein found across the animal kingdom. In mice, specific combinations of these proteins completely blocked the lethal effects of rattlesnake venom, and even worked to some degree against venoms from snakes that split off the rattlesnake family tree tens of millions of years ago, though the protection wasn’t perfect across the board.

No Single Protein Stopped the Venom, But Pairs Did

Rattlesnake venom is packed with a class of destructive proteins that shred tissue, blow open blood vessel walls, and wreck the body’s ability to clot blood. These proteins, known as metalloproteinases, make up roughly half of all the protein in Western Diamondback venom by weight. They’re the reason a rattlesnake bite causes such dramatic bruising, swelling, and bleeding.

Rattlesnakes survive their own bites partly because their blood carries built-in blockers for these proteins. Researchers found five FETUA proteins in the Western Diamondback rattlesnake. One, FETUA-1, is essentially the same ancient protein humans and most other animals with backbones carry too. The other four are unique to the rattlesnake lineage, and each one blocks a different piece of the venom’s destructive machinery.

No single protein could do the job alone. FETUA-2 completely stopped the bleeding in mouse experiments but only partly protected against death. FETUA-3 did almost the opposite: it shut down venom activity in lab tests but did nothing for bleeding and offered no protection on its own. Put the two together, though, and every mouse in the test survived a dose three times higher than what’s normally fatal, with no outward signs of envenomation. Blocking these destructive proteins alone was enough to prevent death from rattlesnake venom, something not previously shown for this kind of venom. Against a different rattlesnake species that split off the family tree roughly 5.5 to 7 million years ago, the recipe needed a third protein, FETUA-5, to fully work, a reminder that different venoms call for different combinations.

antivenom infographic
Rattlesnake blood holds natural proteins that blocked deadly venom in mice, hinting at a future snakebite treatment. (Image by StudyFinds)

Protection Extended to Venoms 34 Million Years Removed

Researchers were not expecting how far these proteins could reach beyond their own species. A three-protein mix fully protected every mouse tested against venom from Calloselasma rhodostoma, an Asian pit viper whose family split from rattlesnakes some 34 million years ago. A four-protein mix also helped significantly against a second Asian species, Deinagkistrodon acutus, though four of ten treated mice still died.

Researchers then went further still, testing true vipers, an entirely separate branch that split from pit vipers more than 40 million years ago. Against Echis carinatus sochureki, a dangerous saw-scaled viper found across South Asia and the Middle East, the mix significantly boosted survival. Against Bitis arietans, the African puff adder, it stopped venom activity in lab tests but couldn’t save the mice from a lethal dose.

A look at snake genomes helped explain why this cross-species overlap happens at all: true vipers carry closely related versions of these same proteins. The core building blocks likely existed in a common ancestor shared by pit vipers and true vipers roughly 50 million years ago, even as individual species have since gained, lost, or reshuffled the exact set they carry today.

Ten Times Less Protein Neutralized the Same Venom Dose

Potency matters because it determines the dose. In a lab test where the proteins were mixed with venom before injection, the three-protein combination neutralized Western Diamondback venom using roughly one-tenth the amount, by weight, of CroFab, the leading commercial antivenom, and worked about seven times as efficiently molecule for molecule. A lower dose could someday translate to lower costs and fewer side effects, though nobody has proven that yet for these proteins specifically. Part of the edge may come down to precision: rather than flooding the body with a broad mix of antibodies that may or may not hit the right targets, each FETUA protein goes straight after a specific destructive enzyme.

A real catch remains, though. Every one of the animal survival trials mixed the proteins with venom before injecting mice, which is not how snakebite actually happens. Whether the proteins can still work as a rescue treatment, given after venom is already spreading through the body, remains untested. Safety in humans, proper dosing, and how long the proteins last in the bloodstream are all still unknown. Two of the study’s authors also hold pending patents tied to this work.

For more than a hundred years, snakebite victims have depended on the immune systems of horses and sheep. This time, the blueprint for something better may have been sitting in the snake’s own blood all along.


Disclaimer: This article describes early-stage laboratory research conducted in mice and does not represent medical advice. The proteins discussed have not been tested in humans, have not been approved as a treatment, and should not be interpreted as a substitute for seeking immediate medical care for snakebite. Anyone bitten by a venomous snake should seek emergency medical treatment right away.


Paper Notes

Study Limitations

All lethality and hemorrhage tests in this study were conducted in mice, and the researchers used a pre-incubation method, meaning the FETUA proteins were mixed with venom before being injected into the animals. This setup does not replicate real-world snakebite treatment, where antivenom is administered after a bite has already occurred. Whether these proteins can protect animals in a rescue scenario, after venom has already entered the bloodstream and begun causing damage, has not yet been tested. Several experiments involved small groups of mice, with as few as five animals receiving a given protein combination. Protection varied considerably by species: some venoms were fully neutralized, others only partially, and Bitis arietans venom showed no survival benefit despite inhibition of enzyme activity in lab tests. The study also relied on proteins from Western Diamondback rattlesnakes; whether proteins from species more closely matched to specific target species would perform better remains an open question. Safety, immune response, and pharmacokinetic behavior of FETUA proteins in living systems have not been evaluated, and all results are from animal models.

Funding and Disclosures

This work was funded by the Howard Hughes Medical Institute, the Andrew and Mary Balo and Nicholas and Susan Simon Endowed Chair at the University of Maryland, and the Viper Resource Center grant #P40OD01960-22 at the National Natural Toxins Research Center, Texas A&M University-Kingsville. Two of the authors are co-inventors on pending patents related to this work, with the University of Maryland as the assignee (U.S. Patent App. No. 63/431,147 and 63/994,480).

Publication Details

Authors: Sean B. Carroll, Fiona P. Ukken, Yetunde A. Ayinuola, Luis Escalona, Montamas Suntravat, and Elda E. Sanchez. Carroll and Ukken contributed equally to this work. Author affiliations include HHMI and the University of Maryland-College Park, and the National Natural Toxins Research Center and Department of Chemistry at Texas A&M University-Kingsville. | Journal: Proceedings of the National Academy of Sciences (PNAS), 2026, Vol. 123, No. 32 | Paper Title: ‘Nature’s antivenom: Combinations of conserved rattlesnake serum metalloproteinase inhibitors block the lethal action of viper venoms’ | DOI: https://doi.org/10.1073/pnas.2612168123 | Published: July 29, 2026


About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor

Leave a Comment